IMUGENE LIMITED — Board/Management Information 2014

Apr 22, 2014

==> picture [152 x 32] intentionally omitted <==

Gastric cancer specialist joins Imugene Scientific Advisory Board

Melbourne, 23 April 2014: Australian immuno-oncology company Imugene Limited (ASX:IMU) has appointed US gastrointestinal cancer expert Dr Neil Segal to its Scientific Advisory Board (SAB).

Dr Segal is an oncologist at the Memorial Sloan Kettering Cancer Center, the oldest and largest private cancer centre in the US. His research interests focus on the development of new therapies and more specifically, ways to use the immune system to treat cancer. This parallels the approach taken with Imugene’s HER-Vaxx vaccine, which aims to activate the patient’s immune system to produce its own antibodies.

"It is marvellous for Imugene to secure an oncologist of Dr Segal’s reputation for the SAB,” said Dr Nick Ede, executive director of Imugene.

“As well as being a show of confidence in the science and the company his experience as a gastric physician will benefit Imugene as it progresses towards and through Phase II trials for HER-Vaxx in patients with gastric cancer.”

Dr Segal has further clinical expertise in colorectal, pancreatic, bile duct and other gastrointestinal cancers. He holds a Doctorate of Medicine and Philosophy from University of the Witwatersrand in South Africa.

Contact :

Paul A Hopper Executive Chairman +1 858 334 5820 (US) +61 406 671 515 (Australia) receptogen[at]earthlink.net

Dr Nick Ede Executive Director +61 400 642 254 nede[at]imugene.com

Media contact: Rudi Michelson Monsoon Communications +61 3 9620 3333 rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology company developing clinical cancer vaccines to advance cancer care. The Company’s lead product is HER-Vaxx, a proprietary therapeutic cancer vaccine that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com

Imugene Limited A.C.N: 009 179 551 Suite 1, 1233 High Street, Armadale, VIC, 3142 Phone: 03 9824 5254 Fax: 03 9822 7735